Enhertu could fill a gastric hole
The first-line Destiny-Gastric05 trial includes a PD-L1-negative cohort.
Novartis gets a PSMAfore green flag at last
Pre-chemo prostate cancer beckons, but Pluvicto has a long way to go to hit $5bn sales.
Pfizer dials down its atirmociclib ambitions
The company is stepping back in second-line breast cancer.
Imfinzi puts its flag on the Matterhorn
A hit on EFS will challenge regulators, and points to Merck's design blunder in Keynote-585.
Hello BridgeBio, farewell Syros and Achilles
One step forward, two steps back for biotech.
FDA red and green lights: February 2025
Adcetris bags its eighth approval, while SpringWorks and Ono also feature.
The month ahead: March's upcoming events
Another SERD catalyst and the son of Darzalex take centre stage.
Regeneron shoots again with odronextamab
The company hits an FDA-mandated enrolment target, but only in follicular lymphoma.
